- Home
- DOUG vs VTYX Comparison
DOUG vs VTYX Comparison
Compare DOUG & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOUG
- VTYX
- Stock Information
- Founded
- DOUG 1911
- VTYX 2018
- Country
- DOUG United States
- VTYX United States
- Employees
- DOUG N/A
- VTYX N/A
- Industry
- DOUG Building operators
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- DOUG Real Estate
- VTYX Health Care
- Exchange
- DOUG Nasdaq
- VTYX Nasdaq
- Market Cap
- DOUG 161.5M
- VTYX 154.9M
- IPO Year
- DOUG N/A
- VTYX 2021
- Fundamental
- Price
- DOUG $2.39
- VTYX $2.98
- Analyst Decision
- DOUG
- VTYX Buy
- Analyst Count
- DOUG 0
- VTYX 4
- Target Price
- DOUG N/A
- VTYX $11.33
- AVG Volume (30 Days)
- DOUG 690.2K
- VTYX 889.8K
- Earning Date
- DOUG 07-31-2025
- VTYX 08-07-2025
- Dividend Yield
- DOUG N/A
- VTYX N/A
- EPS Growth
- DOUG N/A
- VTYX N/A
- EPS
- DOUG N/A
- VTYX N/A
- Revenue
- DOUG $1,034,406,000.00
- VTYX N/A
- Revenue This Year
- DOUG $17.61
- VTYX N/A
- Revenue Next Year
- DOUG N/A
- VTYX N/A
- P/E Ratio
- DOUG N/A
- VTYX N/A
- Revenue Growth
- DOUG 8.69
- VTYX N/A
- 52 Week Low
- DOUG $1.35
- VTYX $0.78
- 52 Week High
- DOUG $3.20
- VTYX $3.39
- Technical
- Relative Strength Index (RSI)
- DOUG 48.88
- VTYX 53.31
- Support Level
- DOUG $2.11
- VTYX $2.54
- Resistance Level
- DOUG $2.59
- VTYX $2.94
- Average True Range (ATR)
- DOUG 0.20
- VTYX 0.23
- MACD
- DOUG -0.01
- VTYX -0.02
- Stochastic Oscillator
- DOUG 41.23
- VTYX 54.37
About DOUG Douglas Elliman Inc.
Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate. Business is engaged in two operating segments Real Estate Brokerage and Corporate and other. The firm generates income from Commission and other brokerage revenue from existing home sales, Commission and other brokerage income from development marketing, Property management revenue and Title fees. It derives revenue from Real Estate Brokerage segment.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.